NFGCM
SPRY icon

Norman Fields Gottscho Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

Norman Fields Gottscho Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$569K Buy
71,080
+31,230
+78% +$269K 0.17% 46
2026
Q1 		$320K Buy
+39,850
New +$382K 0.11% 56

Other funds holding SPRY

PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.46B AUM 21.89% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Norman Fields Gottscho Capital Management's SPRY Position: Q2 2026 in Review

Norman Fields Gottscho Capital Management increased its ARS Pharmaceuticals (SPRY) stake by 78% in Q2 2026, buying an estimated $269K and bringing the position to 71,080 shares worth $569K. The position accounts for 0.17% of the portfolio, ranked #46.

Norman Fields Gottscho Capital Management first reported a position in SPRY in Q1 2026 and has held it in 2 quarters since. 8 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Norman Fields Gottscho Capital Management held 71,080 shares of ARS Pharmaceuticals worth $569K as of Q2 2026.
  • Norman Fields Gottscho Capital Management bought 31,230 ARS Pharmaceuticals shares in Q2 2026, an estimated $269K.
  • ARS Pharmaceuticals made up 0.17% of Norman Fields Gottscho Capital Management's portfolio in Q2 2026, its #46 holding.
  • Norman Fields Gottscho Capital Management first reported a position in ARS Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 8 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Norman Fields Gottscho Capital Management's 13F filing for Q2 2026, filed 8 Jul 2026.